通过聚合激活降解剂选择性去除病态
Jonathan Benn1, Shi Cheng1, Sophie Keeling1
1UK Dementia Research Institute at the University of Cambridge, Cambridge CB2 0AH, UK.
Science (New York, N.Y.)
|August 29, 2024
概括
研究人员开发了一种新方法来选择性地降解病态蛋白质聚合物,如tau,使用工程TRIM21RING域与纳米体融合. 这种方法有望通过清除有毒蛋白质而保持正常蛋白质来治疗神经退行性疾病
科学领域:
- 分子生物学
- 神经科学
- 生物技术
背景情况:
- 选择性降解病态蛋白质聚合物是关键的治疗目标.
- E3结合酶TRIM21特别降解与抗体结合的蛋白质,但很难准细胞内聚合物.
研究的目的:
- 设计细胞内结构以选择性降解组装的蛋白质.
- 评估TRIM21RING-纳米体融合对蛋白质聚合的有效性.
主要方法:
- 将TRIM21RING域与特定的纳米体融合在一起.
- 创建了用于蛋白质降解的细胞内表达结构.
- 在体外和体内对H2B-GFP和tau聚合进行了测试.
主要成果:
- 设计的RING纳米体降解剂可以选择性地消除组装的蛋白质.
- 在细胞和动物模型中阻止和逆转tau聚合.
- 显示对单体水平的影响最小.
结论:
- 这种新的方法有效地准并降解细胞内蛋白质组合.
- 在蛋白质聚合引起的神经退行性疾病中,RING纳米体降解剂具有治疗潜力.
相关概念视频
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
01:26Alzheimer's Disease: Overview
454
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
454